GST-π、TOPO-Ⅱ在非小细胞肺癌化疗前的表达及其临床意义  

EXPRESSION AND ITS CLINICAL SIGNIFICANCE OF GST-Π,TOPO-Ⅱ IN NON SMALL-CELL LUNG CANCER BEFORE CHEMOTHERAPY

作　　者：王立红[1] 李国华[1] 孙勤暖[2] 顾岩[1] 付秀华[1] 张卿[1] 

机构地区：[1]内蒙古医学院附属医院呼吸内科,内蒙古呼和浩特010050 [2]内蒙古医学院病理科

出　　处：《内蒙古医学院学报》2007年第3期160-163,共4页Acta Academiae Medicinae Neimongol

基　　金：国家自然科学基金(30560175)

摘　　要：目的:探讨谷胱甘肽S转移酶-π(GST-π)、DNA拓扑异构酶-Ⅱ(TOPO-Ⅱ)在非小细胞肺癌(NSCLC)化疗前的表达及其临床意义。方法:采用免疫组化双染色法检测97例肺癌组织及21例癌旁组织中GST-π、TOPO-Ⅱ的表达水平。结果:肺癌组织中GST-π、TOPO-Ⅱ的阳性表达率分别为64.95%、60.83%,其表达与性别、年龄、TNM分期及淋巴结转移无显著相关性(P>0.05)。GST-π的阳性表达率则随着分化程度的降低而降低,而TOPO-Ⅱ的阳性表达率随着分化程度的降低而升高,两者的阳性表达率在高分化与低分化组间均有显著性差异(P<0.05)。GST-π的阳性表达率与组织类型无关,而TOPO-Ⅱ的阳性表达率在鳞状细胞癌中明显高于腺癌(P<0.05)。结论:在NSCLC中存在原发耐药。联合检测化疗前NSCLC中耐药蛋白GST-π、TOPO-Ⅱ的表达,为临床治疗方案的选择提供有益的信息。Objective：To investigate the expression and its clinical significance of glutathione transferase - π （ GST - Ⅱ）, DNA topoisomerase - π （ GST - Ⅱ） in non small - ceil lung cancer （NSCLC） before chemotherapy. Methods..Immunohistochemistry double color technique was used to evaluated the expression of GST - π,TOPO - Ⅱ in cancer tissues of 97 cases of NSCLC and 21 cases of paracancerous tissues. Results ： The positive rates of GST - π, TOPO - Ⅱ in NSCLC were 64.95%, 60. 83%, which were not correlated with sex,age,TNM stage and lymph node metastasis （P 〉 0. 05） ; The positive rate of GST -π was decreased with lowerly differentiated carcinomas, but the positive rate of TOPO - Ⅱ was increased with lowerly differentiated carcinomas, both the positive rates were significantly different between highly and lowly differentiated carcinomas （P 〈 0. 05） ;The positive rate of GST-π was not correlated with histological types, but the positive rate of TOPO- Ⅱ was significantly higher in squamous ceil carcinoma than that in adenocarcinoma （P 〈 0. 05） . Conclusion： Primary drug resistance exists in NSCLC . To examine the expression of GST -π, TOPO - Ⅱ together before chemotherapy in NSCLC can offer beneficial information for the choice of the clinical therapeutic ways.

关 键 词：肺癌 谷胱甘肽S转移酶-Π DNA拓扑异构酶-Ⅱ 免疫组化 

分 类 号：R721.53[医药卫生—儿科] R734.1[医药卫生—临床医学]